Natera (NASDAQ:NTRA) Share Rating Reaffirmed by Piper Sandler

Piper Sandler reiterated its overweight rating on the stock Natera (NASDAQ:NTRA – Free Report) in a research note published on Friday, Benzinga reports. They currently have a $150.00 price target on the medical research company’s stock.

A number of other brokerages recently weighed in on NTRA. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a buy rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group raised their target price on Natera from $130.00 to $145.00 and gave the stock a buy rating in a research report on Tuesday, August 27th. BTIG Research boosted their price objective on Natera from $125.00 to $135.00 and gave the company a buy rating in a research report on Friday, August 9th. TD Cowen upped their target price on shares of Natera from $137.00 to $145.00 and gave the company a buy rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group assumed coverage on shares of Natera in a research report on Monday, June 3rd. They issued a buy rating and a $142.00 target price on the stock. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $120.07.

Get the latest stock report on NTRA

Natera stock up 1.1%

Shares of NTRA stock opened at $126.51 on Friday. Natera has a 12-month low of $36.90 and a 12-month high of $128.28. The company has a quick ratio of 4.01, a current ratio of 4.14, and a debt-to-equity ratio of 0.34. The company has a market cap of $15.65 billion, a price-to-earnings ratio of -40.55 and a beta of 1.53. The company has a 50 day moving average of $112.73 and a two hundred day moving average of $103.97.

Natera (NASDAQ:NTRA – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s revenue increased by 58.1% year-on-year. In the same quarter last year, the company posted ($0.97) earnings per share. On average, equities analysts anticipate that Natera will post -1.96 earnings per share for the current fiscal year.

Insiders place their bets

In related news, CFO Michael Burkes Brophy sold 499 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the sale, the chief financial officer now owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC’s website. In related news, CFO Michael Burkes Brophy sold 499 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total value of $53,592.60. Following the transaction, the chief financial officer now owns 77,418 shares in the company, valued at $8,314,693.20. The transaction was disclosed in a filing with the SEC, which is available via this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The disclosure for this sale can be found here. Insiders have sold a total of 86,283 shares of company stock worth $9,523,685 over the last 90 days. 7.60% of shares are currently owned by insiders.

Hedge funds affect Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Itau Unibanco Holding SA bought a new stake in shares of Natera in the second quarter worth $28,000. Principal Securities Inc. bought a new position in Natera in the 4th quarter valued at about $32,000. Quarry LP boosted its stake in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares during the last quarter. Finally, YHB Investment Advisors Inc. purchased a new position in shares of Natera in the first quarter worth about $36,000. Institutional investors and hedge funds own 99.90% of the company’s shares.

Natera Company Profile

(Get a free report)

Natera, Inc, a diagnostics company, develops and markets molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that assesses chromosomal abnormalities in a fetus as well as in twin pregnancies; The Horizon Carrier Screening Test for individuals and couples determines whether they carry genetic variations that cause certain genetic conditions; The Vistara Single-Gene NIPT evaluates 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora which analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further reading

Get news and reviews for Natera Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Natera and related companies with MarketBeat.com’s FREE daily email newsletter.